Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
BioSpace23h
After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build-Out Is ‘Over Our Skis’
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
Mounjaro and Zepbound Sales Soar, Pushing Eli Lilly's (LLY) Q4 Revenue to New Highs
Eli Lilly posts robust Q4 earnings as Mounjaro and Zepbound sales more than double, lifting full-year revenue by 32% ...
Benzinga.com27d
FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?
Zepbound is an injectable prescription medication ... The medication also promotes weight loss, with patients losing an average of 45 pounds or 18% of their body weight, during the trials.
Medical News Today10d
How to Get Zepbound: Your Guide to Getting a Zepbound Prescription
As a result, healthcare professionals may prescribe another GLP-1 medication that works in a similar way to encourage weight loss. Although all Zepbound doses are currently available, individual ...
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...